Somewhat at odds with the atRA resistance conferred by the FLT3-ITD in the mouse model, an exome sequencing study on matched diagnosis-relapse samples from patients with APL that had been treated with atRA plus chemotherapy showed that FLT3 mutations present at diagnosis were consistently lost at relapse [72]. The gene discussed is FLT3; the disease is acute promyelocytic leukemia.